Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Liposarcoma 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1Colorectal Neoplasms 1

Interventions

Paclitaxel 6Cyclophosphamide 5pembrolizumab 3Taxes 3Specimen Handling 3Doxorubicin 3Carboplatin 3eribulin 2Trastuzumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sargramostim 1ruxolitinib 1pertuzumab 1onvansertib 1olaparib 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Radiotherapy 1Radiation 1Panitumumab 1Palliative Care 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Gonadotropin-Releasing Hormone 1Exercise Test 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Inflammatory Breast Neoplasms × eribulin × Clear all
NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
37 enrolled
Breast

Inflammatory Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
22 enrolled 12 charts
Breast

Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡